Abstract
This study was designed to investigate the effects of combination of omega-3-fattyacids and simvastatin on lipoproteins, in patients with mixed dyslipidemia. Among the 371 patients screened 312 who met the inclusion criteria after 6weeks on a strict diet therapy were grouped into two treatment groups. The inclusion criteria were mixed dyslipidemia with a high triglyceride level (200-499mg per 100ml) and a total cholesterol level more than 200mg per 100ml.Retrospective study was conducted on dyslipidemicpatients receiving simvastatin alone (20mg)and combination of simvastatin (20mg)andomega 3 fattyacidssupplements (4gm)daily for 12weeks. The lipoproteins level were monitored. After 12 weeks treatment, triglycerides level (Tc, TG, HDL, LDL) was found significantly decreasedin the combination therapy (Simvastatin and Omega-3-fatty acids) than the simvastatin monotherapy. From the result it is concluded that combination therapy may be considered as an optimal treatment option for patients with mixed dyslipidemia.
References
G. Parthasarathi, K. N. Hansen, M. C. Nahata. A textbook of clinical pharmacy practice, Orient longman, Hyderabad, 2004; 8; 84-90.
Connor WE, Cerqueira MT, Connor RW, Wallace RB, Malinow MR, Casdorph HR. Theplasma,lipids, lipoproteins, and diet of the Tarahumara Indians of Mexico. Am J Clinical Nutrition 1978; 31:1131-1142.
Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J BiolChem 1929; 82:345-367.
Manchila-Caravalho JJ, Crews DE Lipid profiles of Yanomamo Indians of Brazil. Prev Med 1990;19:66-75
Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J BiolChem 1929; 82:345-367.
Moller’s Grunnlagt, Mechanism of omega fatty acid: www.mollersomega3.com
Lars E. Schmidt and Kim Dalhoff .. Food-Drug Interactions .Drugs. 2002;62(10)1481-1502
George M Brenner, Craig W Steven’s: “principles of pharmacology”, Elsevier Health Sciences Marketing, New Delhi, Edition 2nd, 2008.
HL Sharma KK Sharma: “Principles of pharmacology”, paras marketing, Hyderabad, Edition 2nd,
Neal M. Davies, Andrew J.Mclachlan, Ric.O.Day and Kenneth M. Williams. Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib.A selective cyclo-oxygenase -2 inhibitor. Clin. Pharmacokinets.2000; 38(3);225-242.
Sang-Hyun Min-Kyung Kim, Hae-Young, Hyun-Jae Kang, Young-Jin Kim and Hyo-Soo Kim Prospective randomizedbetween omega-3fatty acid supplements plus simvastatin versus simvastatin alone in korean patients with mixed dyslipdemia lipoprotein profiles and heart rate variability. European Journal of Clinical Nutrition 2011, 65,110-116.
.Teddy kosoglou, ingomeyer, enrico p .veltri, paulstatkevich, bo yang, yalizhu, Lilianmellaras, StephenE.Maxwelll, jamesE.patrick, David L. cutler, vijay k. Batra, and meltonb.affrime. Pharmacodynamicinteraction between the new selective cholesterol absorbtion inhibitor ezetimide and simvastatin. British journal of clinical pharmaology 2002;54, 309-319.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array